Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen

Newer products, including Otezla, Repatha, MVASI, KANJINTI and Evenity, partially offset declines due to biosimilar competition

By: Contract Pharma

Contract Pharma Staff

Amgen
1Q Revenues: $6.2 billion (+11%)
1Q Earnings: $1.8 billion (-8%)
Comments: Growth across newer products, including Otezla, Repatha, MVASI, KANJINTI and Evenity, partially offset declines in several products from the impact of biosimilar and generic competition. Enbrel sales were $1.2 billion. Prolia sales were $654 million in the quarter, up 10%. Aranesp sales were $422 million, up 2%. Repatha sales were $229 million, up 62%. Evenity sales reached $100 million in the quarter. Otezla sales were $479 million. KYPROLIS sales were $280 million, up 14%. XGEVA sales were $481 million, up 2%. Vectibix sales were $202 million, up 19%. Nplate sales were $218 million, up 15%. Neulasta sales were down 40% to $609 million. NEUPOGEN sales were down 11% to $65 million. EPOGEN sales were down 29% to $155 million. Sensipar/Mimpara sales were down 42% to $123 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters